Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03665207 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tight Versus Liberal Blood Glucose Control in Adult Critically Ill Patients

Study acronym: TGC-fast
StatusActive, Not Recruiting
PhasePhase 3
SponsorKU Leuven
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 5 to 4
    • Primary completion date changed from estimate of Dec 2022 to Nov 30, 2022
    • Study completion date: Jan 2026 to Nov 2026
    v5
  2. Primary completion date: Jan 2022 to Dec 2022v4
  3. Primary completion date: Sep 2021 to Jan 2022
    • Study completion date: Sep 2025 to Jan 2026
    • Site details revised at 3 of 5 sites
    • Eligibility criteria expanded, about 1 word
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2018 to Sep 18, 2018
    • Site details revised at 5 of 5 sites
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
KU Leuven
69 trials monitored
See all monitored trials
Critically ill patients usually develop hyperglycemia, which is associated with an increased risk of morbidity and mortality. Controversy exists on whether targeting normal blood glucose concentrations with insulin therapy, referred to as tight blood glucose control (TGC) improves outcome of these patients, as compared to tolerating hyperglycemia. It remains unknown whether TGC, when applied with optimal tools to avoid hypoglycemia, is beneficial in a context of withholding early parenteral nutrition. The TGC-fast study hypothesizes that TGC is beneficial in adult critically ill patients not receiving early parenteral nutrition, as compared to tolerating hyperglycemia.
Trial Details
NCT Number NCT03665207
Lead Sponsor KU Leuven
Collaborators: Universitaire Ziekenhuizen KU Leuven, Research Foundation Flanders
Conditions
(from sponsor)		 Critical Illness, Hyperglycemia
Related terms Critical Illness, Hyperglycemia
Enrollment 9,230 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov